
Pilar Blancafort

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4254302/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Breastmilk Is a Novel Source of Stem Cells with Multilineage Differentiation Potential. Stem Cells, 2012, 30, 2164-2174.	3.2	215
2	Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics, 2012, 7, 350-360.	2.7	189
3	Development of Zinc Finger Domains for Recognition of the 5′-CNN-3′ Family DNA Sequences and Their Use in the Construction of Artificial Transcription Factors. Journal of Biological Chemistry, 2005, 280, 35588-35597.	3.4	166
4	Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. Molecular Therapy, 2013, 21, 358-367.	8.2	164
5	Designing Transcription Factor Architectures for Drug Discovery. Molecular Pharmacology, 2004, 66, 1361-1371.	2.3	162
6	Evaluation of a Modular Strategy for the Construction of Novel Polydactyl Zinc Finger DNA-Binding Proteinsâ€. Biochemistry, 2003, 42, 2137-2148.	2.5	161
7	Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Research, 2012, 40, 6725-6740.	14.5	138
8	Scanning the human genome with combinatorial transcription factor libraries. Nature Biotechnology, 2003, 21, 269-274.	17.5	120
9	Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA. Chemical Science, 2017, 8, 2923-2930.	7.4	101
10	Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene, 2007, 26, 2791-2798.	5.9	87
11	Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. Npj Precision Oncology, 2020, 4, 24.	5.4	86
12	Generation of tumor-initiating cells by exogenous delivery of OCT4transcription factor. Breast Cancer Research, 2011, 13, R94.	5.0	81
13	Gene expression in breastmilk cells is associated with maternal and infant characteristics. Scientific Reports, 2015, 5, 12933.	3.3	77
14	Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene, 2014, 33, 4767-4777.	5.9	76
15	Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing. Methods in Molecular Biology, 2018, 1767, 19-63.	0.9	73
16	Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene, 2015, 34, 5427-5435.	5.9	71
17	Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System. Molecular Therapy - Nucleic Acids, 2019, 14, 287-300.	5.1	68
18	Epigenome Engineering in Cancer: Fairytale or a Realistic Path to the Clinic?. Frontiers in Oncology, 2015. 5. 22	2.8	63

PILAR BLANCAFORT

#	Article	IF	CITATIONS
19	Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget, 2016, 7, 60535-60554.	1.8	61
20	Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene, 2020, 39, 1167-1184.	5.9	61
21	Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor <i>mammary serine protease inhibitor</i> . Molecular Cancer Therapeutics, 2008, 7, 1080-1090.	4.1	58
22	Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Research, 2014, 42, 10856-10868.	14.5	56
23	Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. Oncogene, 2019, 38, 140-150.	5.9	55
24	Hallmarks of cancer: The CRISPR generation. European Journal of Cancer, 2018, 93, 10-18.	2.8	54
25	In Vivo Selection of Combinatorial Libraries and Designed Affinity Maturation of Polydactyl Zinc Finger Transcription Factors for ICAM-1 Provides New Insights into Gene Regulation. Journal of Molecular Biology, 2004, 341, 635-649.	4.2	49
26	Cisplatin Induces Differentiation of Breast Cancer Cells. Frontiers in Oncology, 2013, 3, 134.	2.8	48
27	Suppression of Breast Tumor Growth and Metastasis by an Engineered Transcription Factor. PLoS ONE, 2011, 6, e24595.	2.5	45
28	Genetic reprogramming of tumor cells by zinc finger transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11716-11721.	7.1	44
29	Rab GTPases: Emerging Oncogenes and Tumor Suppressive Regulators for the Editing of Survival Pathways in Cancer. Cancers, 2020, 12, 259.	3.7	43
30	Reactivation of <i>MASPIN</i> in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics, 2011, 6, 224-235.	2.7	42
31	Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. Journal of Biological Chemistry, 2012, 287, 29873-29886.	3.4	38
32	Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. Chemical Science, 2019, 10, 7718-7727.	7.4	37
33	Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102003.	3.3	36
34	Epigenome engineering: new technologies for precision medicine. Nucleic Acids Research, 2020, 48, 12453-12482.	14.5	34
35	Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation. Molecular Therapy, 2016, 24, 536-547.	8.2	33
36	Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules. Molecular Pharmacology, 2013, 83, 563-576.	2.3	30

PILAR BLANCAFORT

#	Article	IF	CITATIONS
37	Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 53.	4.6	30
38	Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland. Frontiers in Oncology, 2013, 3, 79.	2.8	28
39	Promoter-targeted Phage Display Selections with Preassembled Synthetic Zinc Finger Libraries for Endogenous Gene Regulation. Journal of Molecular Biology, 2004, 340, 599-613.	4.2	26
40	Modulation of drug resistance by artificial transcription factors. Molecular Cancer Therapeutics, 2008, 7, 688-697.	4.1	22
41	Interrogating Genomes with Combinatorial Artificial Transcription Factor Libraries: Asking Zinc Finger Questions. Assay and Drug Development Technologies, 2006, 4, 317-331.	1.2	20
42	Breaking through an epigenetic wall. Epigenetics, 2013, 8, 164-176.	2.7	20
43	Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 361.	4.6	19
44	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nature Communications, 2021, 12, 1920.	12.8	19
45	The recognition of a noncanonical RNA base pair by a zinc finger protein. Chemistry and Biology, 1999, 6, 585-597.	6.0	17
46	Rational Design, Selection and Specificity of Artificial Transcription Factors (ATFs): The Influence of Chromatin in Target Gene Regulation. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 146-158.	1.1	17
47	Sequence-Specific Biosensors Report Drug-Induced Changes in Epigenetic Silencing in Living Cells. DNA and Cell Biology, 2012, 31, S-2-S-10.	1.9	15
48	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Molecular Therapy - Methods and Clinical Development, 2021, 21, 592-606.	4.1	11
49	Long live the stem cell: The use of stem cells isolated from post mortem tissues for translational strategies. International Journal of Biochemistry and Cell Biology, 2014, 56, 74-81.	2.8	10
50	Innovative Precision Geneâ€Editing Tools in Personalized Cancer Medicine. Advanced Science, 2020, 7, 1902552.	11.2	9
51	Remodeling Genomes with Artificial Transcription Factors (ATFs). Methods in Molecular Biology, 2010, 649, 163-182.	0.9	9
52	Atomistic molecular dynamics simulations of bioactive engrailed 1 interference peptides (EN1-iPeps). Oncotarget, 2018, 9, 22383-22397.	1.8	9
53	Non-viral Methodology for Efficient Co-transfection. Methods in Molecular Biology, 2018, 1767, 241-254.	0.9	5
54	SP94-Targeted Nanoparticles Enhance the Efficacy of Sorafenib and Improve Liver Cancer Cell Discrimination. ACS Applied Bio Materials, 2021, 4, 1023-1029.	4.6	5

PILAR BLANCAFORT

#	Article	IF	CITATIONS
55	Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor. International Journal of Molecular Sciences, 2021, 22, 9354.	4.1	4
56	Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity. Frontiers in Immunology, 2021, 12, 712722.	4.8	2
57	Poll-driven integrative expression vectors for yeast. Journal of Biotechnology, 1997, 56, 41-47.	3.8	1
58	A peptide-functionalised dendronised polymer for selective transfection in human liver cancer cells. New Journal of Chemistry, 2021, 45, 19315-19320.	2.8	1
59	Breastmilk Stem Cells: Recent Advances and Future Prospects. , 2015, , 185-195.		1
60	Promoter-targeted Phage Display Selections with Preassembled Synthetic Zinc Finger Libraries for Endogenous Gene Regulation. Journal of Molecular Biology, 2004, 340, 599-599.	4.2	0
61	Engineering Transcription Factors in Breast Cancer Stem Cells. , 2011, , .		0
62	G9aâ€induced epigenetic silencing of maspin in human claudinâ€low breast tumor initiating cells. FASEB Journal, 2011, 25, 122.6.	0.5	0
63	Breastmilk and the lactating breast as a tool to elucidate breast cancer. FASEB Journal, 2013, 27, 629.9.	0.5	0
64	The CRISPR road: from bench to bedside on an RNA-guided path. Annals of Translational Medicine, 2015, 3, 174.	1.7	0